Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
REGULATORY
Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
Members of the Central Social Insurance Medical Council (Chuikyo) are calling for the revisiting of health coverage for conditionally approved regenerative medicines following two recent cases of products that ended up being pulled from the market. At a Chuikyo meeting…
To read the full story
Related Article
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
REGULATORY
- FY2025 Budget Request Would Add 7 PMDA Reviewers for Startup Consultations
September 13, 2024
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
- MHLW Lays Out Updated Discussion Timeline for PMD Act Amendment
September 13, 2024
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…